PDS Biotechnology (NASDAQ:PDSB) Stock Lifted to “Hold” by Wall Street Zen

Wall Street Zen upgraded shares of PDS Biotechnology (NASDAQ:PDSB) from a sell rating to a hold rating in a research report report published on Monday morning,Wall Street Zen reports.

PDSB has been the topic of a number of other reports. HC Wainwright reiterated a “buy” rating on shares of PDS Biotechnology in a research note on Wednesday, August 26th. Weiss Ratings raised shares of PDS Biotechnology from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, September 28th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, PDS Biotechnology currently has a consensus rating of “Hold” and an average target price of $9.00.

PDS Biotechnology Price Performance

PDSB stock opened at $1.20 on Monday. The stock’s 50 day moving average is $0.51 and its two-hundred day moving average is $0.79. PDS Biotechnology has a 52-week low of $0.20 and a 52-week high of $1.55. The company has a market capitalization of $67.16 million, a PE ratio of -1.88 and a beta of 1.17. The company has a quick ratio of 0.57, a current ratio of 0.57 and a debt-to-equity ratio of 2.73.

PDS Biotechnology (NASDAQ:PDSB) last released its earnings results on Thursday, August 13th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.05). Analysts predict that PDS Biotechnology will post -0.47 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp bought a new position in PDS Biotechnology during the 2nd quarter worth $60,000. Renaissance Technologies LLC lifted its stake in PDS Biotechnology by 25.0% in the first quarter. Renaissance Technologies LLC now owns 220,800 shares of the company’s stock valued at $134,000 after buying an additional 44,100 shares during the last quarter. Finally, BlackRock Inc. acquired a new position in shares of PDS Biotechnology during the second quarter valued at $535,000. Institutional investors and hedge funds own 26.84% of the company’s stock.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation (NASDAQ:PDSB) is a clinical-stage biotechnology company developing immunotherapies designed to stimulate the immune system to recognize and attack cancer cells. The company’s research is centered on its Versamune platform, which is intended to activate and enhance T-cell responses against specific disease-associated targets.

PDS Biotechnology’s lead programs include PDS0101, an investigational therapeutic candidate designed to generate immune responses against human papillomavirus type 16 (HPV16) antigens.